Advances In Whole Exome Sequencing

This content is brought to you by Integrated DNA Technologies, a Danaher Operating Company.

Whole exome sequencing (WES) has redefined how researchers approach genetic discovery, shifting focus to the protein-coding regions where most disease-associated variants occur. By balancing breadth and efficiency, WES delivers comprehensive insights at a lower cost and faster turnaround than whole genome sequencing—making it an increasingly preferred strategy across oncology and rare disease research. From identifying key biomarkers like TMB, MSI, and HRD to uncovering rare variant–trait associations in large-scale datasets, WES continues to expand the boundaries of what’s possible in precision medicine. Advances in sequencing technology and bioinformatics are further enhancing accuracy, scalability, and long-term data value through reanalysis.

For teams evaluating sequencing strategies or optimizing workflows, exploring how WES compares to targeted panels—and where it excels—can unlock new opportunities for discovery.